Elliott H L, Whiting B, Reid J L
Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):323S-328S. doi: 10.1111/j.1365-2125.1983.tb05881.x.
1 The interaction between mianserin and centrally-acting antihypertensive drugs was evaluated in normal volunteers and in patients with essential hypertension receiving either clonidine or methyldopa. 2 The administration of the first dose of 20 mg mianserin to the normal volunteers was associated with a significant sedative effect and transient postural hypotension. 3 In the normal volunteers, the blood pressure responses to a single oral dose of 300 micrograms clonidine were not modified by pretreatment with mianserin. The bradycardia associated with clonidine alone, however, was significantly attenuated. 4 In the patient study, no significant changes in blood pressure control were observed, either after the first dose of 30 mg mianserin or after one and two weeks' continued treatment with mianserin. 5 There is no evidence from these studies that the addition of mianserin therapy results in a clinically significant impairment of the antihypertensive effects of clonidine or methyldopa.
1 在正常志愿者以及接受可乐定或甲基多巴治疗的原发性高血压患者中,评估了米安色林与中枢性抗高血压药物之间的相互作用。2 给正常志愿者首次服用20毫克米安色林会产生显著的镇静作用和短暂的体位性低血压。3 在正常志愿者中,米安色林预处理并未改变单次口服300微克可乐定后的血压反应。然而,单独使用可乐定引起的心动过缓明显减轻。4 在患者研究中,首次服用30毫克米安色林后或米安色林持续治疗1周和2周后,血压控制均未观察到显著变化。5 这些研究没有证据表明加用米安色林治疗会导致可乐定或甲基多巴的抗高血压作用出现具有临床意义的损害。